{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:33:10Z","timestamp":1790699590987,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd005656.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000}}],"reference-count":183,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005656.pub3","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T19:39:04Z","timestamp":1605728344000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Intravitreal steroids for macular edema in diabetes"],"prefix":"10.1002","volume":"2020","author":[{"given":"Thanitsara","family":"Rittiphairoj","sequence":"additional","affiliation":[{"name":"Department of Epidemiology; Johns Hopkins Bloomberg School of Public Health; Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahreem A","family":"Mir","sequence":"additional","affiliation":[{"name":"Wilmer Eye Institute; Johns Hopkins University School of Medicine; Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University of Colorado Denver Anschutz Medical Campus; Aurora CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Virgili","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA); University of Florence; Florence Italy"},{"name":"Centre for Public Health; Queen's University Belfast; Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD005656.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ajo.2005.05.021","article-title":"Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema","volume":"140","author":"Avitabile","year":"2005","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0002|cit2","first-page":"117","article-title":"Retinal vascular calibre changes in the bevordex randomised clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular oedema","volume":"43","author":"Alessandrello","year":"2015","journal-title":"Clinical and Experimental Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0003|cit3","unstructured":"Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone) Investigative Ophthalmology and Visual Science 2018 59 9"},{"issue":"12","key":"10.1002\/14651858.CD005656.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.ophtha.2014.07.002","article-title":"A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study","volume":"121","author":"Gillies","year":"2014","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1002\/14651858.CD005656.pub3-BIB0005|cit5","first-page":"ARVO E","article-title":"BEVORDEX-a multicentre randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for persistent diabetic macular oedema","volume":"55","author":"Gillies","year":"2014","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00417-016-3472-1","article-title":"A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema","volume":"255","author":"Callanan","year":"2017","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD005656.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ophtha.2009.10.002","article-title":"Factors associated with improvement and worsening of visual acuity 2 years after focal\/grid photocoagulation for diabetic macular edema","volume":"117","author":"Aiello","year":"2010","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD005656.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/archophthalmol.2009.308","article-title":"Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal\/grid photocoagulation","volume":"127","author":"Bressler","year":"2009","journal-title":"Archives of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD005656.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.ophtha.2008.06.015","article-title":"A randomized trial comparing intravitreal triamcinolone acetonide and focal\/grid photocoagulation for diabetic macular edema","volume":"115","author":"Diabetic Retinopathy Clinical Research Network","year":"2008","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/archophthalmol.2008.610","article-title":"Three-year follow-up of a randomized trial comparing focal\/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema","volume":"127","author":"Beck","year":"2009","journal-title":"Archives of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD005656.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/IAE.0b013e31818144a7","article-title":"A randomized trial comparing intravitreal triamcinolone and focal\/grid photocoagulation for diabetic macular edema: baseline features","volume":"28","author":"Ip","year":"2008","journal-title":"Retina"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0012|cit12","unstructured":"Ip MS A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema (DME): study design and baseline characteristics Investigative Ophthalmology and Visual Science 2008 ARVO E abstract 3468"},{"issue":"8","key":"10.1002\/14651858.CD005656.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archophthalmol.2011.214","article-title":"Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the Diabetic Retinopathy Clinical Research Network","volume":"129","author":"Lauer","year":"2011","journal-title":"Archives of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD005656.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3928\/23258160-20160324-01","article-title":"DRCR protocol-T: reconciling 1- and 2-year data for managing diabetic macular edema","volume":"47","author":"Wykoff","year":"2016","journal-title":"Ophthalmic Surgery Lasers and Imaging Retina"},{"issue":"4","key":"10.1002\/14651858.CD005656.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ophtha.2010.12.028","article-title":"Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0016|cit16","unstructured":"Dempe C Scholl S Augustin A Fluocinolone acetonide (FAc) intravitreal implants improve visual acuity in chronic diabetic macular edema (DME) for up to 36 months Acta Ophthalmologica. Conference: 40th Nordic Congress of Ophthalmology, Helsinki, Finland 2012"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ophtha.2013.11.026","article-title":"Refractive changes after pharmacologic resolution of diabetic macular edema","volume":"121","author":"Deak","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD005656.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/eye.2013.242","article-title":"Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results","volume":"28","author":"Kriechbaum","year":"2014","journal-title":"Eye"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1111\/aos.13520","article-title":"Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone","volume":"96","author":"Prager","year":"2018","journal-title":"Acta Ophthalmologica"},{"issue":"2","key":"10.1002\/14651858.CD005656.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000331935","article-title":"Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial","volume":"227","author":"Lim","year":"2012","journal-title":"Ophthalmologica"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12886-015-0148-2","article-title":"Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study","volume":"30","author":"Augustin","year":"2015","journal-title":"BMC Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/IAE.0000000000001004","article-title":"Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study","volume":"36","author":"Maturi","year":"2016","journal-title":"Retina"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0024|cit24","unstructured":"Hykin P Ockrim Z Falk S Sivaprasad S Gregor Z Tufail A A randomized trial of intravitreal triamcinolone vs. macular laser therapy for persistent clinically significant diabetic macular edema The Macula Society 2006 174"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0025|cit25","unstructured":"Ockrim ZK Senswathi S Falk S Ojeda F Schadt M Gregor Z A randomised trial of intravitreal triamcinolone verses macular laser therapy for persistent clinically significant diabetic macular oedema Investigative Ophthalmology and Visual Science 2006 47 13 ARVO E abstract 5438"},{"issue":"6","key":"10.1002\/14651858.CD005656.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/bjo.2007.131771","article-title":"Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema","volume":"92","author":"Ockrim","year":"2008","journal-title":"British Journal of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD005656.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/IAE.0b013e31817f2dae","article-title":"Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema","volume":"28","author":"Sivaprasad","year":"2008","journal-title":"Retina (Philadelphia, Pa.)"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ophtha.2008.12.016","article-title":"Diabetic macular edema","volume":"116","author":"Gillies","year":"2009","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD005656.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1442-9071.2010.02341.x","article-title":"Triamcinolone-induced cataract in eyes with diabetic macular oedema: 3-year prospective data from a randomized clinical trial","volume":"38","author":"Gillies","year":"2010","journal-title":"Clinical and Experimental Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD005656.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.ophtha.2009.04.049","article-title":"Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema","volume":"116","author":"Gillies","year":"2009","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ophtha.2008.09.044","article-title":"Intravitreal triamcinolone","volume":"116","author":"Gillies","year":"2009","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD005656.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.ophtha.2006.02.065","article-title":"Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial","volume":"113","author":"Gillies","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0033|cit33","unstructured":"Gillies MC Sutter FKP Interim (3 month) analysis of the efficacy of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. A randomized clinical trial: TDMO Investigative Ophthalmology and Visual Science 2003 44 13 ARVO E abstract 3219"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0034|cit34","unstructured":"Gillies MC Zhu M Simpson JM Sutter FKP A randomized, placebo-controlled trial of intravitreal triamcinolone acetonide for diabetic macular edema that persists or recurs after laser treatment-2-year results Investigative Ophthalmology and Visual Science 2005 46 13 ARVO E abstract 4672"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0035|cit35","unstructured":"Gillies MC Intravitreal triamcinolone for refractory diabetic macular oedema: 5-year results of a double-masked, placebo-controlled, randomised clinical trial with open label extension Investigative Ophthalmology and Visual Science 2008 49 13 ARVO E abstract 1565"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1755-3768.2008.01245.x","article-title":"Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial","volume":"87","author":"Larsson","year":"2009","journal-title":"Acta Ophthalmologica"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0037|cit37","unstructured":"Larsson J Wang J Kifley A Mitchell P Sutter F Zhu M Effect of intravitreal triamcinolone on hard exudates in patients with diabetic retinopathy-a pilot, randomized controlled clinical trial Investigative Ophthalmology and Visual Science 2005 46 13 ARVO E abstract 1444"},{"issue":"11","key":"10.1002\/14651858.CD005656.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2004.05.025","article-title":"Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial","volume":"111","author":"Sutter","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0039|cit39","unstructured":"Sutter FKP Gillies MC Interim (3 month) analysis of the safety of intravitreal triamcinolone for diabetic macular oedema that persists after laser treatment. Results from a randomized clinical trial: TDMO Investigative Ophthalmology and Visual Science 2003 44 13 ARVO E abstract 4003"},{"issue":"11","key":"10.1002\/14651858.CD005656.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1167\/iovs.08-1678","article-title":"Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema","volume":"49","author":"Wickremasinghe","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0041|cit41","unstructured":"Zhu M Larsson J Jamal H Gillies M Correlation between intraocular pressure, visual acuity and reduction of foveal thickness in diabetic macular oedema treated with intravitreal triamcinolone Investigative Ophthalmology and Visual Science 2005 46 13 ARVO E abstract 1439"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0042|cit42","unstructured":"A multicentre randomised clinical trial of laser treatment plus 4 mg intravitreal triamcinolone injection to reduce diabetic macular oedema apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ACTRN12605000245695"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0043|cit43","unstructured":"Ali M Khan FA Zafar S Akhtar F Short and long term intraocular pressure changes after intravitreal injections of triamcinolone acetonide and bevacizumab in diabetic macular edema Rawal Medical Journal 2014 39 4 443 5"},{"issue":"5","key":"10.1002\/14651858.CD005656.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1600-0420.2006.00700.x","article-title":"Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial","volume":"84","author":"Audren","year":"2006","journal-title":"Acta Ophthalmologica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD005656.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2003.05.037","article-title":"Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial","volume":"111","author":"Massin","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Massin PG Audren F Erginay A Haouchine B Bergmann JF Gaudric A Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: results of a prospective controlled trial Investigative Ophthalmology and Visual Science 2004 45 13 ARVO E abstract 3463","DOI":"10.1167\/iovs.03-1110"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4103\/0974-620X.106100","article-title":"Comparison of intravitreal bevacizumab, intravitreal triamcinolone acetonide, and macular grid augmentation in refractory diffuse diabetic macular edema: a prospective, randomized study","volume":"5","author":"Azad","year":"2012","journal-title":"Oman Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0048|cit48","unstructured":"Bandello F Polito A Dimastrogiovanni A Palsslos I Intravitreal triamcinolone associated with grid laser photocoagulation for diffuse diabetic macular edema Macular Society Annual Meeting 2004"},{"issue":"9","key":"10.1002\/14651858.CD005656.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"A804","DOI":"10.1016\/j.jval.2017.08.3068","article-title":"Cost-effectiveness of a 0.2 MG\/day fluocinolone acetonide (FAC) implant in the treatment chronic diabetic macular oedema (DMO) in the UK","volume":"20","author":"Beiderbeck","year":"2017","journal-title":"Value in Health"},{"issue":"12","key":"10.1002\/14651858.CD005656.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1001\/archophthalmol.2009.304","article-title":"Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the Diabetic Retinopathy Clinical Research Network laser-ranibizumab-triamcinolone clinical trials","volume":"127","author":"Bhavsar","year":"2009","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ajo.2007.04.011","article-title":"The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials","volume":"144","author":"Bhavsar","year":"2007","journal-title":"American Journal of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD005656.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1167\/iovs.05-0297","article-title":"Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial","volume":"46","author":"Bonini-Filho","year":"2005","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Bressler SB Glassman AR Almukhtar T Bressler NM Googe JM Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema American Journal of Ophthalmology 2016 164 57 68","DOI":"10.1016\/j.ajo.2015.12.025"},{"issue":"7","key":"10.1002\/14651858.CD005656.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.ophtha.2009.11.024","article-title":"Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ajo.2016.04.017","article-title":"Pro-permeability factors in diabetic macular edema; the Diabetic Macular Edema Treated with Ozurdex trial","volume":"168","author":"Campochiaro","year":"2016","journal-title":"American Journal of Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD005656.pub3-BIB0056|cit56","first-page":"3283","article-title":"Sustained intraocular delivery of fluocinolone acetonide slows progression of diabetic retinopathy","volume":"57","author":"Campochiaro","year":"2016","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"9","key":"10.1002\/14651858.CD005656.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.ophtha.2005.03.023","article-title":"Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema","volume":"112","author":"Cardillo","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0058|cit58","doi-asserted-by":"crossref","unstructured":"Chakrabarti A Chakrabarti M Stephen V John SR Biridhar A A comparative analysis of various treatment modalities for recalcitrant diabetic macula edema American Academy of Ophthalmology 2007","DOI":"10.1155\/2007\/69527"},{"issue":"1","key":"10.1002\/14651858.CD005656.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3341\/kjo.2007.21.1.11","article-title":"Laser photocoagulation combined with intravitreal triamcinolone acetonide injection in proliferative diabetic retinopathy with macular edema","volume":"21","author":"Choi","year":"2007","journal-title":"Korean Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD005656.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3349\/ymj.2008.49.6.955","article-title":"Comparison of combination posterior sub-Tenon triamcinolone and modified grid laser treatment with intravitreal triamcinolone treatment in patients with diffuse diabetic macular edema","volume":"49","author":"Chung","year":"2008","journal-title":"Yonsei Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD005656.pub3-BIB0061|cit61","first-page":"15","article-title":"Confounding factors influencing the effect of intravitreal triamcinolone for refractory diabetic macular edema","volume":"3","author":"Ahmadieh","year":"2007","journal-title":"EVRS Educational Electronic Journal"},{"issue":"1","key":"10.1002\/14651858.CD005656.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10792-007-9097-y","article-title":"A randomized, placebo-controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema","volume":"28","author":"Dehghan","year":"2008","journal-title":"International Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD005656.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00417-011-1777-7","article-title":"Comparative study of vitrectomy versus intravitreous triamcinolone for diabetic macular edema on randomized paired-eyes","volume":"250","author":"Doi","year":"2012","journal-title":"Graefe's Archive for Clinical & Experimental Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD005656.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1097\/IAE.0b013e31822a042a","article-title":"Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema","volume":"31","author":"Elbendary","year":"2011","journal-title":"Retina"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2147\/OPTH.S36609","article-title":"Intravitreal autologous plasmin as a therapeutic modality for diffuse diabetic macular edema","volume":"6","author":"Elsawy","year":"2012","journal-title":"Clinical Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD005656.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000088385","article-title":"Intravitreal cortisone injection for refractory diffuse diabetic macular edema","volume":"219","author":"Er","year":"2005","journal-title":"Ophthalmologica"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0067|cit67","unstructured":"Evaluation of Iluvien for the treatment of DME apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-001680-37-ES"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0068|cit68","unstructured":"Comparison of the efficacy of treatment of retinal macular inflammation due to diabetes with ozurdex or with ozurdex plus laser treatment in the area apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-003870-41-ES"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0069|cit69","unstructured":"Frey M T\u00f6nz MS Brinkmann CK Wolf-Schurrbusch UEK Wolf S Comparison of short-term effects after intravitreal application of triamcinolone and Avastin\u00ae (bevacizumab) in patients with diabetic macular edema Investigative Ophthalmology and Visual Science 2008 49 13 ARVO E abstract 3512"},{"issue":"5","key":"10.1002\/14651858.CD005656.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF03163806","article-title":"Therapy of macular edema with an intravitreal dexamethasone implant","volume":"20","author":"Georgopoulos","year":"2006","journal-title":"Spektrum der Augenheilkunde"},{"issue":"2","key":"10.1002\/14651858.CD005656.pub3-BIB0071|cit71","first-page":"98","article-title":"Therapy of macular edema with an intravitreal dexamethasone implant","volume":"19","author":"Georgopoulos","year":"2005","journal-title":"Spektrum der Augenheilkunde"},{"issue":"5","key":"10.1002\/14651858.CD005656.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1590\/S0004-27492011000500007","article-title":"Treatment of diffuse diabetic maculopathy with intravitreal triamcinolone and laser photocoagulation: randomized clinical trial with morphological and functional evaluation","volume":"74","author":"Gil","year":"2011","journal-title":"Arquivos Brasileiros de Oftalmologia"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0073|cit73","doi-asserted-by":"crossref","unstructured":"Heng LZ Sivaprasad S Crosby-Nwaobi R Saihan Z Karampelas M Bunce C A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser only in centre-involving diabetic macular oedema (OZLASE study) British Journal of Ophthalmology 2016 100 6 802 7","DOI":"10.1136\/bjophthalmol-2015-307136"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/eye.2013.265","article-title":"Local safety of repeated intravitreal Ozurdex","volume":"28","author":"Hernandez-Martinez","year":"2014","journal-title":"Eye"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0075|cit75","unstructured":"INVICTUS: intravitreal anti-VEGF and dexamethasone implant comparison for the treatment of diabetic macular edema: a 6 months follow-up Study Acta ophthalmologica 2019"},{"issue":"1","key":"10.1002\/14651858.CD005656.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1755-3768.2009.01817.x","article-title":"Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study","volume":"90","author":"Isaac","year":"2012","journal-title":"Acta Ophthalmologica"},{"issue":"2","key":"10.1002\/14651858.CD005656.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/ceo.13371","article-title":"Dexamethasone implant for the treatment of persistent diabetic macular oedema despite long-term treatment with bevacizumab","volume":"47","author":"Joe","year":"2019","journal-title":"Clinical and Experimental Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD005656.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.ajo.2004.07.007","article-title":"Inter-eye difference in diabetic macular edema after unilateral intravitreal injection of triamcinolone acetonide","volume":"138","author":"Jonas","year":"2004","journal-title":"American Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1089\/jop.2006.22.200","article-title":"Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study","volume":"22","author":"Jonas","year":"2006","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"12","key":"10.1002\/14651858.CD005656.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00417-007-0640-3","article-title":"Triamcinolone versus inner-limiting membrane peeling in persistent diabetic macular edema (TIME study): design issues and implications","volume":"245","author":"Joussen","year":"2007","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0081|cit81","unstructured":"Joussen AM Weiss C Wolf S Kirchhof B Hilgers RD Triamcinolone versus inner-limiting membrane peeling for diffuse macular edema (TIME study): design issues and implications Investigative Ophthalmology and Visual Science 2005 46 13 ARVO E abstract 1468"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0082|cit82","unstructured":"WP-0508ST Phase ll\/lll clinical trial apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-JapicCTI-132139"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0083|cit83","unstructured":"Anti-VEGF and steroid combination therapy for diabetic macular edema apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000021630"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0084|cit84","first-page":"36","article-title":"A prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema undergoing cataract surgery (the dimecat trial)-6-month results","volume":"46","author":"Kandasamy","year":"2018","journal-title":"Clinical and Experimental Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0085|cit85","doi-asserted-by":"crossref","unstructured":"Kandasamy R Constantinou M Sandhu SS Wickremasinghe S Al-Qureshi S Prospective randomised clinical trial of intravitreal bevacizumab versus triamcinolone in eyes with diabetic macular oedema undergoing cataract surgery: 6-month results British Journal of Ophthalmology 2019 103 12 1753 8","DOI":"10.1136\/bjophthalmol-2018-313437"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.12659\/MSM.910923","article-title":"The effects of intravitreal ranibizumab, aflibercept or dexamethasone implant injections on intraocular pressure changes","volume":"24","author":"Karakurt","year":"2018","journal-title":"Medical Science Monitor"},{"issue":"2","key":"10.1002\/14651858.CD005656.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1111\/aos.12504","article-title":"Short-term efficacy of intravitreal triamcinolone acetonide for bevacizumab-resistant diabetic macular oedema","volume":"93","author":"Kim","year":"2015","journal-title":"Acta Ophthalmologica"},{"issue":"4","key":"10.1002\/14651858.CD005656.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000284466","article-title":"Comparison of intravitreal bevacizumab versus triamcinolone for the treatment of diffuse diabetic macular edema","volume":"224","author":"Kreutzer","year":"2010","journal-title":"Ophthalmologica"},{"issue":"7","key":"10.1002\/14651858.CD005656.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/IAE.0b013e3181dcfaf3","article-title":"Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema","volume":"30","author":"Blumenkranz","year":"2010","journal-title":"Retina"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archophthalmol.2010.21","article-title":"Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema","volume":"128","author":"Haller","year":"2010","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0091|cit91","unstructured":"Haller JA Weinberg D Chou C Ip M Davis M Whitcup SM Correlation of macular thickness and visual acuity in patients with persistent macular edema Investigative Ophthalmology and Visual Science 2006 47 13 ARVO E abstract 5908"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0092|cit92","unstructured":"Haller JA Weinberg DV Chou C lp MS Davis MD Whitcup SM Correlation of visual acuity and macular thickness as measured by OCT in patients with persistent macular edema American Academy of Ophthalmology 2006 297"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archopht.125.3.309","article-title":"Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema","volume":"125","author":"Kuppermann","year":"2007","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0094|cit94","unstructured":"Kuppermann BD Blumenkranz MS Haller JA Williams GA Posurdex Study Group An intravitreous dexamethasone bioerodible drug delivery system for the treatment of persistent diabetic macular edema Investigative Ophthalmology and Visual Science 2003 44 13 ARVO E abstract 4289"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0095|cit95","unstructured":"Kuppermann BD Chou C Weinberg DV Whitcup DV Haller JA Blumenkranz MS Response to a sustained-release dexamethasone posterior-segment drug delivery system for different patterns of diabetic macular edema American Academy of Ophthalmology 2005 249"},{"issue":"5","key":"10.1002\/14651858.CD005656.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/archophthalmol.2010.44","article-title":"Intravitreous dexamethasone effects on different patterns of diabetic macular edema","volume":"128","author":"Kuppermann","year":"2010","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0097|cit97","unstructured":"Kuppermann BD Haller JA Williams GA Blumenkranz MS A randomized controlled trial to assess the safety and efficacy of a dexamethasone implant for diabetic macular edema American Academy of Ophthalmology 2003 150"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0098|cit98","unstructured":"Williams GA Haller JA Kuppermann BD Blumenkranz MS Weinberg DV Chou C Evaluation of an intravitreous dexamethasone drug delivery system in patients with persistent diabetic macular edema American Academy of Ophthalmology 2006 192"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"243","DOI":"10.7150\/ijms.3971","article-title":"Comparison of natural course, intravitreal triamcinolone and macular laser photocoagulation for treatment of mild diabetic macular edema","volume":"10","author":"Kwon","year":"2013","journal-title":"International Journal of Medical Sciences"},{"issue":"12","key":"10.1002\/14651858.CD005656.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.ophtha.2007.02.006","article-title":"Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes","volume":"114","author":"Lam","year":"2007","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD005656.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1442-9071.2009.02104.x","article-title":"Factors associated with variability in response of diabetic macular oedema after intravitreal triamcinolone","volume":"37","author":"Mohamed","year":"2009","journal-title":"Clinical and Experimental Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD005656.pub3-BIB0102|cit102","first-page":"ARVO E","article-title":"Early central subfield thickness and long-term visual acuity changes with fluocinolone acetonide (FAc)-associated continuous microdosing in diabetic macular edema","volume":"58","author":"Luo","year":"2017","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2147\/OPTH.S22103","article-title":"Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema","volume":"5","author":"Marey","year":"2011","journal-title":"Clinical Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0104|cit104","first-page":"634","article-title":"Evaluation of an intravitreous dexamethasone drug delivery system in patients with persistent diabetic macular oedema","volume":"20","author":"Massin","year":"2010","journal-title":"European Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0105|cit105","doi-asserted-by":"crossref","unstructured":"Maturi RK Bleau L Saunders J Mubasher M Stewart MW A 12-month, single-masked, randomized controlled study of eyes with persistent diabetic macular edema after multiple anti-vegf injections to assess the efficacy of the dexamethasone-delayed delivery system as an adjunct to bevacizumab compared with continued bevacizumab monotherapy Retina 2015 35 8 1604 14","DOI":"10.1097\/IAE.0000000000000533"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0106|cit106","unstructured":"Ranibizumab or aflibercept therapy with dexamethosone intravitreal injection efficacy in diabetic macular edema Investigative Ophthalmology and Visual Science 2018 59 9"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0107|cit107","unstructured":"Efficacy of ranibizumab plus aflibercept therapy with dexamethosone intravitreal injection in patients with diabetic macular edema-1 year follow-up Investigative Ophthalmology and Visual Science 2020 61 7"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0108|cit108","unstructured":"Triamcinolone acetonide injections to treat diabetic macular edema clinicaltrials.gov\/ct2\/show\/NCT00231023"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0109|cit109","unstructured":"Safety and effectiveness of ozurdex steroid implants for DME after vitrectomy surgery clinicaltrials.gov\/ct2\/show\/NCT01788475"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0110|cit110","unstructured":"Acute pseudophakic cystoid macular edema treatment trial: intravitreal ranibizumab versus triamcinolone acetonide clinicaltrials.gov\/ct2\/show\/NCT02294656"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0111|cit111","unstructured":"Prospective, randomized clinical trial comparing macular photocoagulation with or without intravitreal bevacizumab or triamcinolone for the treatment of diabetic macular edema clinicaltrials.gov\/ct2\/show\/NCT02310295"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0112|cit112","unstructured":"Dexamethasone intravitreal implant for the treatment of persistent diabetic macular edema clinicaltrials.gov\/ct2\/show\/NCT02471651"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0113|cit113","unstructured":"Bevacizumabe or triamcinolone for persistent diabetic macular edema (BEVATAAC) clinicaltrials.gov\/ct2\/show\/NCT02985619"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0114|cit114","unstructured":"The Use of a Combination of Ozurdex and Eylea Versus Eylea Monotherapy for Diabetic Macular Edema: a Prospective, Comparative Trial (COED Trial) https:\/\/clinicaltrials.gov\/show\/NCT03984110 (first received 21 October 2020)"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0115|cit115","doi-asserted-by":"crossref","unstructured":"Neto HO Regatieri CV Nobrega MJ Muccioli C Casella AM Andrade RE Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema Ophthalmic Surgery, Lasers and Imaging Retina 2017 48 9 734 40","DOI":"10.3928\/23258160-20170829-08"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2415-11-36","article-title":"Intravitreal triamcinolone versus laser photocoagulation as a primary treatment for diabetic macular oedema-a comparative pilot study","volume":"11","author":"Norlaili","year":"2011","journal-title":"BMC Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0117|cit117","unstructured":"Oliveira GP Paes JP Camilo ER Corr\u0119a SB Paiva MM Baccelli PE The use of intra-vitreal Avastin injection in diabetic patients with macular edema Investigative Ophthalmology and Visual Science 2007 48 13 ARVO E Abstract 5035"},{"issue":"6","key":"10.1002\/14651858.CD005656.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/IAE.0000000000002537","article-title":"Comparison of intravitreal dexamethasone implant and aflibercept in patients with treatment-naive diabetic macular edema with serous retinal detachment","volume":"40","author":"Ozsaygili","year":"2020","journal-title":"Retina"},{"issue":"1","key":"10.1002\/14651858.CD005656.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/bjo.2007.129122","article-title":"Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study)","volume":"92","author":"Paccola","year":"2008","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0120|cit120","unstructured":"Reviewed by Pearson PA Steroids implant reduces retinal thickness, improves vision Ophthalmology Times 24 6"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0121|cit121","unstructured":"Pearson PA Baker CW Eliott D Ip MS Morese LS Callanan DG Fluocinolone acetonide intravitreal implant for diabetic macular edema: 2 year results Investigative Ophthalmology and Visual Science 2004 45 13 ARVO E abstract 4673"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0122|cit122","unstructured":"Pearson PA Baker CW Eliott D Ip MS Morese LS Callanan DG Fluocinolone acetonide intravitreal implant in patients with diabetic macular edema American Academy of Ophthalmology Annual Meeting 2002"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0123|cit123","unstructured":"Pearson PA Eliott D Baker CW Ip MS Morese LS Callanan DG Fluocinolone acetonide intravitreal implant in patients with diabetic macular edema Association for Research in Vision and Ophthalmology Annual Meeting 2003"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0124|cit124","unstructured":"Reviewed by Pearson PA Patients with DME have response to fluocinolone acetonide intravitreal implant in study outcomes Ophthalmology Times 38"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0125|cit125","unstructured":"Pearson PA Bevy B Fluconolone Acetonide Implant Study Group Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 2-year results of a multi-center clinical trial Association for Research in Vision and Ophthalmology Annual Meeting 2005"},{"issue":"8","key":"10.1002\/14651858.CD005656.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2011.02.048","article-title":"Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial","volume":"118","author":"Pearson","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0127|cit127","unstructured":"Pearson PA Levy B Comstock T Fluocinolone Acetonide Implant Study Group Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multi-center clinical trial Investigative Ophthalmology and Visual Science 2006 47 13 ARVO E abstract 5442"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0128|cit128","unstructured":"Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema Acta ophthalmologica 2019"},{"issue":"2","key":"10.1002\/14651858.CD005656.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1111\/aos.13905","article-title":"Change in choroidal volume after dexamethasone intravitreal implant in eyes with diabetic macular oedema","volume":"97","author":"Posch-Pertl","year":"2019","journal-title":"Acta Ophthalmologica"},{"issue":"4","key":"10.1002\/14651858.CD005656.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1590\/S0004-27492008000400005","article-title":"Use of intravitreal triamcinolone and laser photocoagulation for the treatment of diffuse diabetic macular edema","volume":"71","author":"Saraiva","year":"2008","journal-title":"Arquivos Brasileiros de Oftalmologia"},{"issue":"2","key":"10.1002\/14651858.CD005656.pub3-BIB0131|cit131","first-page":"71","article-title":"Visual acuity outcome in patients with diabetic maculopathy","volume":"7","author":"Serban","year":"2014","journal-title":"Journal of Medicine and Life"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0132|cit132","doi-asserted-by":"crossref","unstructured":"Shah SU Harless A Bleau L Maturi RK Prospective randomized subject-masked study of intravitreal bevacizumab monotherapy versus dexamethasone implant monotherapy in the treatment of persistent diabetic macular edema Retina 2016 36 10 1986 96","DOI":"10.1097\/IAE.0000000000001038"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4103\/0974-9233.65496","article-title":"A prospective, randomized comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab (Avastin) in diffuse diabetic macular edema","volume":"17","author":"Shahin","year":"2010","journal-title":"Middle East African Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0134|cit134","unstructured":"Anti-VEGF versus dexamethasone implant (Ozurdex) for the management of Centre involved Diabetic Macular Edema (CiDME): a randomized study International ophthalmology 2019"},{"issue":"5","key":"10.1002\/14651858.CD005656.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ajo.2007.12.031","article-title":"Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema","volume":"145","author":"Shimura","year":"2008","journal-title":"American Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD005656.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000331322","article-title":"Comparison of grid laser, intravitreal triamcinolone, and intravitreal bevacizumab in the treatment of diffuse diabetic macular edema","volume":"227","author":"Sobaci","year":"2012","journal-title":"Ophthalmologica"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0137|cit137","doi-asserted-by":"crossref","unstructured":"Sonoda S Sakamoto T Yamashita T Otsuka H Shirasawa M Kakiuchi N Effect of intravitreal triamcinolone acetonide or bevacizumab on choroidal thickness in eyes with diabetic macular edema Investigative Ophthalmology and Visual Science 2014 55 6 3979 85","DOI":"10.1167\/iovs.14-14188"},{"issue":"8","key":"10.1002\/14651858.CD005656.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/bjo.2004.062596","article-title":"Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema","volume":"89","author":"Spandau","year":"2005","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0139|cit139","unstructured":"Stolba U Binder S Krebs I Aggermann T Vitrectomy versus intravitreal triamcinolon in eyes with persistent diffuse diabetic macular edema-a prospective trial Investigative Ophthalmology and Visual Science 2005 46 13 ARVO E abstract 1453"},{"issue":"4","key":"10.1002\/14651858.CD005656.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/1080768041725308","article-title":"A prospective controlled trial to evaluate the adjunctive role of posterior subtenon triamcinolone in the treatment of diffuse diabetic macular edema","volume":"20","author":"Verma","year":"2004","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD005656.pub3-BIB0141|cit141","first-page":"1355","article-title":"Intravitreal injection of triamcinolone acetonide for macular edema","volume":"7","author":"Yu","year":"2007","journal-title":"International Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD005656.pub3-BIB0142|cit142","first-page":"798","article-title":"Investigation on effects of intravitreal injection of bevacizumab and triamcinolone acetonide for diabetes macular edema","volume":"13","author":"Zhang","year":"2013","journal-title":"International Eye Science"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0143|cit143","doi-asserted-by":"crossref","unstructured":"Ziemssen F Agostini H Re: Boyer et al.: Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema Ophthalmology 2015 122 3 e20 1","DOI":"10.1016\/j.ophtha.2014.08.016"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0144|cit144","unstructured":"McKee KM Hong G Gordon GM Piereamici DJ Dexamethasone Intravitreal Implant versus Intravitreal Anti-VEGF for the Treatment of Persistent Diabetic Macular Edema, Twelve Month Study Analysis (DIME Study) Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2610"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0145|cit145","unstructured":"Yahia SB Attia S Hmidi K Thabti A Zaouali S Messaoud R Intravitreal bevacizumab vs. intravitreal triamcinolone for diabetic macular edema with severe hard exudates American Academy of Ophthalmology 2008 181"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0146|cit146","unstructured":"Chakrabarti M Chakrabarti A Stephen V John S Intravitreal monotherapy with bevacizumab and triamcinolone acetonide vs. combination therapy for recalcitrant diabetic macular edema American Academy of Ophthalmology 2008 263"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0147|cit147","unstructured":"Evaluation of the flare levels and central macular thickness after intravitreal injection of ranibizumab, aflibercept or triamcinolone acetonide in diabetic macular edema patients apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000025769"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0148|cit148","unstructured":"A safety and efficacy study of dexamethasone versus laser photocoagulation in patients with diabetic macular edema clinicaltrials.gov\/ct2\/show\/NCT02121262"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0149|cit149","unstructured":"Anti-VEGF Therapy Versus Dexamethasone Implant for DME https:\/\/clinicaltrials.gov\/show\/NCT03999125 (first received 21 October 2020)"},{"issue":"4","key":"10.1002\/14651858.CD005656.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/08820539909069541","article-title":"The pathogenesis of edema in diabetic maculopathy","volume":"14","author":"Antcliff","year":"1999","journal-title":"Seminars in Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD005656.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jphs.2018.11.001","article-title":"Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: a systematic review of real-world studies","volume":"138","author":"Bucolo","year":"2018","journal-title":"Journal of Pharmacological Sciences"},{"issue":"8","key":"10.1002\/14651858.CD005656.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/bjophthalmol-2018-312284","article-title":"Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries","volume":"103","author":"Chakravarthy","year":"2019","journal-title":"British Journal of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD005656.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2337\/diacare.26.9.2653","article-title":"Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies","volume":"26","author":"Ciulla","year":"2003","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.icu.0000120711.35941.76","article-title":"Corticosteroids in posterior segment disease: an update on new delivery systems and new indications","volume":"15","author":"Ciulla","year":"2004","journal-title":"Current Opinions in Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0155|cit155","unstructured":"Covidence systematic review software Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org"},{"issue":"1","key":"10.1002\/14651858.CD005656.pub3-BIB0156|cit156","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006127.pub2","article-title":"Blood pressure control for diabetic retinopathy","author":"Do","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD005656.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0161-6420(78)35693-1","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy: the second report of DRS findings","volume":"85","author":"Diabetic Retinopathy Study Research Group","year":"1978","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD005656.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1","volume":"103","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1985","journal-title":"Archives of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD005656.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"185-222","DOI":"10.1159\/000458539","article-title":"Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA)","volume":"237","author":"Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"issue":"11","key":"10.1002\/14651858.CD005656.pub3-BIB0160|cit160","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011234.pub2","article-title":"Laser photocoagulation for proliferative diabetic retinopathy","author":"Evans","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD005656.pub3-BIB0161|cit161","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"1","key":"10.1002\/14651858.CD005656.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12886-018-0779-1","article-title":"A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema","volume":"18","author":"He","year":"2018","journal-title":"BMC Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0163|cit163","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0164|cit164","doi-asserted-by":"crossref","unstructured":"Higgins JPT Savovi\u0107 J Page MJ Elbers RG Sterne JAC Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch8"},{"issue":"7","key":"10.1002\/14651858.CD005656.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1080\/03007995.2018.1560779","article-title":"Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trial","volume":"35","author":"Holden","year":"2019","journal-title":"Current Medical Research and Opinion"},{"issue":"10","key":"10.1002\/14651858.CD005656.pub3-BIB0166|cit166","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010859.pub2","article-title":"Monotherapy laser photocoagulation for diabetic macular oedema","author":"Jorge","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD005656.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.2337\/dc15-2171","article-title":"Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010","volume":"39","author":"Leasher","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","article-title":"Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss","volume":"2","author":"Lee","year":"2015","journal-title":"Eye Vis (Lond)"},{"issue":"11","key":"10.1002\/14651858.CD005656.pub3-BIB0169|cit169","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008721.pub2","article-title":"Anti-vascular endothelial growth factor for proliferative diabetic retinopathy","author":"Martinez-Zapata","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD005656.pub3-BIB0170|cit170","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011599.pub2","article-title":"Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema","author":"Mehta","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0171|cit171","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012314.pub2","article-title":"Different lasers and techniques for proliferative diabetic retinopathy","author":"Moutray","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD005656.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/bjophthalmol-2019-313991","article-title":"Safety of 6000 intravitreal dexamethasone implants","volume":"104","author":"Rajesh","year":"2020","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0173|cit173","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ophtha.2019.10.005","article-title":"A collaborative retrospective study on the efficacy and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema: the European DME registry study","volume":"127","author":"Rosenblatt","year":"2020","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD005656.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1097\/IAE.0000000000001369","article-title":"Safety of intravitreal dexamethasone implant (Ozurdex): The SAFODEX study. Incidence and risk factors of ocular hypertension","volume":"37","author":"Malcl\u00e8s","year":"2017","journal-title":"Retina"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0176|cit176","volume-title":"In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org\/handbook.","author":"Sch\u00fcnemann","year":"2019"},{"issue":"8","key":"10.1002\/14651858.CD005656.pub3-BIB0177|cit177","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008214.pub3","article-title":"Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy","author":"Smith","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD005656.pub3-BIB0178|cit178","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008081.pub2","article-title":"Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy","author":"Virgili","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD005656.pub3-BIB0179|cit179","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub5","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis","author":"Virgili","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005656.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/s41433-019-0739-x","article-title":"The role of steroids in treating diabetic macular oedema in the era of anti-VEGF","volume":"34","author":"Weinberg","year":"2020","journal-title":"Eye (London, England)"},{"issue":"3","key":"10.1002\/14651858.CD005656.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD005656.pub3-BIB0182|cit182","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005656","article-title":"Intravitreal steroids for macular edema in diabetes","author":"Grover","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD005656.pub3-BIB0183|cit183","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005656.pub2","article-title":"Intravitreal steroids for macular edema in diabetes","author":"Grover","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T08:06:12Z","timestamp":1687680372000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005656.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":183,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005656.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,17]]}}}